The Bispecific That Beat R-CHOP: What Epkinly's First-Line DLBCL Win Means for the Future of Lymphoma Treatment

On October 6, 2026, AbbVie and Genmab announced that epcoritamab, their subcutaneous bispecific antibody marketed as Epkinly, had met the primary endpoint of the Phase 3 Epcore DLBCL-2 trial in newly diagnosed diffuse large B-cell lymphoma. The combination of Epkinly plus R-CHOP reduced the risk of disease progression or death by 51% compared with R-CHOP alone, producing a hazard ratio of 0.49 in patients with International Prognostic Index scores of 3 to 5. The same 51% risk reduction held across the broader population of patients with IPI scores of 2 to 5. The safety profile was described as consistent with prior Epkinly data and generally well tolerated.

Those numbers are worth sitting with carefully, because they arrive in a competitive context that makes them more consequential than a standalone Phase 3 readout would normally be. Roche's Polivy, the antibody-drug conjugate that became the first drug to displace R-CHOP as a standard of care in newly diagnosed DLBCL when it was approved in 2023, produced a hazard ratio of 0.73 in its registrational Polarix study. The two trials enrolled different patient populations, used different control arms, and cannot be directly compared. But the hazard ratio gap is large enough that oncologists and payers will notice it, and the conversation about what the first-line DLBCL standard of care should look like is now genuinely open again.

What Epcoritamab Actually Does

Epkinly is a CD20xCD3 bispecific antibody, meaning it simultaneously binds to CD20 on malignant B cells and CD3 on T cells, physically bridging the two and activating the T cell to kill the cancer cell. The mechanism is not new to oncology, but its application in the first-line setting for DLBCL represents a meaningful escalation of ambition. Until recently, bispecific antibodies in lymphoma were reserved for patients who had already failed multiple prior lines of therapy. The Epcore DLBCL-2 data suggest that moving this class of drug earlier, into the initial treatment setting, can produce substantially better outcomes than chemotherapy alone.

The subcutaneous delivery is a practical advantage worth noting. Polivy is administered intravenously, requiring infusion center visits. Epkinly's subcutaneous formulation offers a different logistical profile, though the cytokine release syndrome risk that accompanies T-cell engaging bispecifics means that step-up dosing and monitoring protocols are still required, particularly in the early cycles. The safety data from Epcore DLBCL-2 will need to be examined in detail when full results are presented at a future medical meeting, but the topline characterization of a manageable and consistent profile is an encouraging starting point.

The Competitive Stakes for Roche

Polivy generated 808 million Swiss francs in global sales in the first half of 2026, making it one of Roche's more important growth drivers in a period when the company has faced significant competitive pressure across its oncology portfolio. A first-line approval for Epkinly would place it in direct competition with Polivy for the roughly 25,000 newly diagnosed DLBCL patients in the United States each year, a market that is large by oncology standards and commercially attractive given the severity of the disease and the limited alternatives for patients who relapse.

The hazard ratio comparison will be central to that competitive dynamic. Physicians and guideline committees will be cautious about cross-trial comparisons, and rightly so. The Epcore DLBCL-2 trial enrolled patients with IPI scores of 2 to 5 but assessed its primary endpoint in the higher-risk subgroup of scores 3 to 5, while Polarix enrolled the full IPI 2 to 5 range. Patient selection differences, differences in the control arm, and differences in how progression was assessed can all influence hazard ratios in ways that make direct numerical comparisons unreliable. What the data do establish is that epcoritamab plus R-CHOP is a highly active regimen in high-risk newly diagnosed DLBCL, and that the magnitude of benefit is at least as large as, and potentially larger than, what Polivy plus R-CHP demonstrated in a similar population.

A Comeback Story With Complications

The Epcore DLBCL-2 result arrives after a difficult stretch for the Epkinly program. In January 2026, AbbVie and Genmab reported that the Phase 3 Epcore DLBCL-1 trial, which tested epcoritamab monotherapy against investigator's choice chemotherapy in relapsed or refractory DLBCL, had improved progression-free survival but failed to show a statistically significant improvement in overall survival, which was the sole U.S. primary endpoint. The stock fell, the program's trajectory looked uncertain, and questions arose about whether the drug could compete in a setting where CAR-T cell therapy had already established itself as a transformative option for eligible patients.

The first-line data reframe that narrative substantially. A drug that cannot demonstrate an overall survival benefit in the third-line setting, where patients are heavily pretreated and the disease is biologically heterogeneous, may nonetheless produce meaningful and durable benefit when deployed earlier, before the tumor has had the opportunity to evolve resistance mechanisms and before the patient's immune system has been exhausted by multiple prior therapies. The Epcore DLBCL-2 result is consistent with that hypothesis, and it suggests that the optimal role for epcoritamab may be in the front line rather than in the salvage setting.

What Comes Next

AbbVie and Genmab have said they will work with global regulators to determine next steps for the Epcore DLBCL-2 data. A regulatory submission for a first-line indication would represent a significant expansion of Epkinly's label, which currently covers third-line or later DLBCL under the FDA's accelerated approval pathway. The company also reported positive Phase 3 data in June 2026 for Epkinly plus lenalidomide in relapsed or refractory DLBCL patients who had received at least one prior line of treatment, giving the program multiple potential label expansions to pursue simultaneously.

The broader implication of the Epcore DLBCL-2 result extends beyond AbbVie and Genmab. It is a data point in a larger argument about where bispecific antibodies belong in the treatment of aggressive B-cell lymphomas. The field has been moving steadily toward earlier use of these agents, driven by the logic that T-cell engaging mechanisms are most effective when the immune system is intact and the tumor burden is manageable. If the first-line data hold up under regulatory scrutiny and translate into a label change, the DLBCL treatment landscape will look meaningfully different from what it does today. R-CHOP, the regimen that has anchored lymphoma treatment for more than two decades, may finally be on the verge of being replaced not by a single successor but by a generation of combination regimens built around immune-engaging mechanisms that the field is only beginning to understand how to use optimally.